Achilles Therapeutics plc

Our CEO Iraj Ali shares his insights with the BioIndustry Association (BIA) Association Community about the recent strides made in oncology research and what the future could hold. He is inspired by the dedication and innovation of researchers in the UK and worldwide working to develop more effective and targeted therapies. At Achilles Therapeutics plc we are using our AI-driven technology to identify target clonal neoantigens for new therapeutic treatments and vaccines for cancer patients. Read the full article here: https://lnkd.in/dT4xmbss #ThoughtLeadership #Oncology #Preciision #CancerResearch #Neoantigens #Clonals

June marks LGBTQ+ Pride Month. For Achilles Therapeutics plc this month is an opportunity to reflect on our commitment to diversity and inclusion. These values are integral to our corporate culture and vital for driving innovation through a variety of perspectives and experiences. To mark #PrideMonth, we are again supporting organizations including the Elton John AIDS Foundation. To find out more about these charities and how you can donate to their cause, visit https://lnkd.in/dnwdSS5 #Oncology #Neoantigens #Clonals

Delighted to be part of this exciting collaboration, funded by EU Horizon: Genesis: A modular protein language modelling approach to immunogenicity prediction https://lnkd.in/gh3daNei

Really happy to share a link to our most recent preprint: https://lnkd.in/enDQ42fp   In it we describe the development of a state-of-the-art immunogenicity predictor, laying the necessary foundation for the DECOD-Ag program. Great collaboration with Marc Mansour, Yardena Samuels, Charles Swanton, Sine Reker Hadrup, UCL Cancer Institute, and Achilles Therapeutics plc, funded by #EUHorizon2020 (EU Science, Research and Innovation).

Today we unveiled a new collaboration with Arcturus Therapeutics, a late clinical-stage messenger RNA medicines company. The collaboration will combine Achilles Therapeutics plc’s best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading sa-mRNA platform to develop self-amplifying personalized mRNA cancer vaccines targeting clonal neoantigens. To read the full press release visit: https://lnkd.in/eTWZ6MQ9 #Collaboration #Oncology #Precision #CancerResearch #Neoantigens #Clonals

Achilles Therapeutics plc’s CSO Sergio Quezada was recently interviewed at the Immuno-Oncology 360° Summit in Boston. Sergio discussed how research into clonal neoantigens, which are mutations present on all tumor cells, opened up an important avenue for precision cell therapies. At Achilles Therapeutics plc, we are developing a next-generation targeted TIL therapy, using our cutting-edge, proprietary bioinformatics platform (PELEUS™) which has the unique ability to define the best neoantigens. To watch the full interview visit: https://lnkd.in/e4xddvRv  #IO360 #Conference #Oncology #Precision #CancerResearch #Neoantigens #Clonals

Pleased to see that His Majesty will be a Patron of Cancer Research UK (CRUK). On the King's recent visit, His Majesty met with Cancer Research UK’s Chief Clinician and Achilles Therapeutics plc co-founder, Professor Charlie Swanton and Achilles co-founder & CMO Karl Peggs.

May is National Cancer Research Month in the United States. At Achilles Therapeutics plc, our goal is to target clonal neoantigens - cancer’s Achilles heel - with the goal of eliminating tumors while preserving the healthy tissues. To learn more about our work in non-small cell lung cancer (NSCLC) and melanoma, visit: https://lnkd.in/e6Q-cv3D. #CancerAwarenessMonth #Oncology #Precision #CancerResearch #Neoantigens #Clonals

Sergio Quezada, Achilles Therapeutics plc's CSO, will be participating in the ‘Synergizing Innovation: Uniting Biotech and Pharma for Advancing AI in Healthcare’ panel at the annual LSX World Congress in London, UK, on April 30 at 11:50am BST.   Please reach out to the team to connect. #Conference #LSXWorld #Oncology #LifeSciences